Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline.
However, it seems that this Big Pharma still has more than enough money to invest in upcoming research (such as MIT’s cell squeezer), and lately it has been redirecting its efforts towards immuno-oncology.
All in all, these are happy circumstances for Boston-based Blueprint Medicines, which will receive €40M ($45M) upfront to collaborate on the development of 5 of its preclinical candidates.
Depending on how these small molecule therapies perform in trials, Blueprint could be aiming at over €850M ($965M) in milestones and licenses. A true billion dollar deal.
So, what did catch Roche’s eyes (and wallet)?
This Biotech uses the genetic ‘blueprint’